Item 1. Financial Statements
Item 1. Financial Statements.
HARVARD BIOSCIENCE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands, except share and per share data)
September 30,
December 31,
2025
2024
Assets
Current assets:
Cash and cash equivalents
$
6,817
$
4,108
Accounts receivable, net
12,109
14,866
Inventories
21,604
23,245
Other current assets
3,275
2,898
Total current assets
43,805
45,117
Property, plant and equipment, net
4,990
5,106
Operating lease right-of-use assets
7,500
6,132
Goodwill
9,525
56,324
Intangible assets, net
8,379
11,132
Other long-term assets
3,793
2,833
Total assets
$
77,992
$
126,644
Liabilities and Stockholders' Equity
Current liabilities:
Debt
$
33,967
$
36,956
Accounts payable
5,176
4,787
Contract liabilities
2,879
3,806
Other current liabilities
12,374
9,409
Total current liabilities
54,396
54,958
Deferred tax liability
733
710
Operating lease liabilities
7,332
6,381
Other long-term liabilities
1,463
1,255
Total liabilities
63,924
63,304
Commitments and contingencies - Note 13
Stockholders' equity:
Preferred stock, par value $ 0.01 per share, 5,000,000 shares authorized
-
-
Common stock, par value $ 0.01 per share, 80,000,000 shares authorized: 44,579,665 shares issued and outstanding at September 30, 2025; 44,074,475 shares issued and outstanding at December 31, 2024
446
441
Additional paid-in-capital
237,922
236,579
Accumulated deficit
( 211,863
)
( 158,010
)
Accumulated other comprehensive loss
( 12,437
)
( 15,670
)
Total stockholders' equity
14,068
63,340
Total liabilities and stockholders' equity
$
77,992
$
126,644
See accompanying notes to condensed consolidated financial statements.
1
Table of Contents
HARVARD BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except per share data)
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Revenues
$
20,591
$
21,970
$
62,815
$
69,579
Cost of revenues
8,570
9,205
27,077
28,824
Gross profit
12,021
12,765
35,738
40,755
Sales and marketing expenses
4,613
5,518
14,123
16,817
General and administrative expenses
4,176
5,041
13,623
16,690
Research and development expenses
2,132
2,567
6,642
8,078
Amortization of acquired intangible assets
855
1,334
3,177
3,998
Goodwill impairment - Note 4
-
-
47,951
-
Other operating expenses - Note 1
48
179
512
1,394
Total operating expenses
11,824
14,639
86,028
46,977
Operating income (loss)
197
( 1,874
)
( 50,290
)
( 6,222
)
Other expense:
Interest expense
( 966
)
( 856
)
( 2,559
)
( 2,356
)
Loss on pension settlement
-
( 1,243
)
( 1,243
)
Loss on equity securities - Note 6
-
-
-
( 1,593
)
Other expense, net
( 365
)
( 518
)
( 1,333
)
( 841
)
Total other expense
( 1,331
)
( 2,617
)
( 3,892
)
( 6,033
)
Loss before income taxes
( 1,134
)
( 4,491
)
( 54,182
)
( 12,255
)
Income tax expense (benefit)
97
311
( 329
)
168
Net loss
$
( 1,231
)
$
( 4,802
)
$
( 53,853
)
$
( 12,423
)
Loss per share:
Basic and diluted loss per share
$
( 0.03
)
$
( 0.11
)
$
( 1.22
)
$
( 0.29
)
Weighted-average common shares:
Basic and diluted
44,556
43,614
44,320
43,499
See accompanying notes to condensed consolidated financial statements.
2
Table of Contents
HARVARD BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited, in thousands)
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Net loss
$
( 1,231
)
$
( 4,802
)
$
( 53,853
)
$
( 12,423
)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments
( 753
)
1,596
3,161
685
Defined benefit pension plans
-
470
-
470
Derivative instruments
18
( 257
)
72
( 24
)
Other comprehensive (loss) income
( 735
)
1,809
3,233
1,131
Comprehensive loss
$
( 1,966
)
$
( 2,993
)
$
( 50,620
)
$
( 11,292
)
See accompanying notes to condensed consolidated financial statements.
3
Table of Contents
HARVARD BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited, in thousands)
Accumulated
Number
Additional
Other
Total
of Shares
Common
Paid-in
Accumulated
Comprehensive
Stockholders’
Issued
Stock
Capital
Deficit
Loss
Equity
Balance at June 30, 2025
44,531
$
445
$
237,622
$
( 210,632
)
$
( 11,702
)
$
15,733
Vesting of restricted stock units
94
1
-
-
-
1
Shares withheld for taxes
( 45
)
-
( 24
)
-
-
( 24
)
Stock-based compensation
-
-
324
-
-
324
Net loss
-
-
-
( 1,231
)
-
( 1,231
)
Other comprehensive loss
-
-
-
-
( 735
)
( 735
)
Balance at September 30, 2025
44,580
$
446
$
237,922
$
( 211,863
)
$
( 12,437
)
$
14,068
Accumulated
Number
Additional
Other
Total
of Shares
Common
Paid-in
Accumulated
Comprehensive
Stockholders’
Issued
Stock
Capital
Deficit
Loss
Equity
Balance at June 30, 2024
43,611
$
436
$
234,905
$
( 153,226
)
$
( 14,868
)
$
67,247
Stock option exercises
6
-
15
-
-
15
Stock-based compensation
-
-
1,053
-
-
1,053
Net loss
-
-
-
( 4,802
)
-
( 4,802
)
Other comprehensive income
-
-
-
-
1,809
1,809
Balance at September 30, 2024
43,617
$
436
$
235,973
$
( 158,028
)
$
( 13,059
)
$
65,322
Accumulated
Number
Additional
Other
Total
of Shares
Common
Paid-in
Accumulated
Comprehensive
Stockholders’
Issued
Stock
Capital
Deficit
Loss
Equity
Balance at December 31, 2024
44,074
$
441
$
236,579
$
( 158,010
)
$
( 15,670
)
$
63,340
Stock purchase plan
123
-
46
46
Vesting of restricted stock units
536
5
-
-
-
5
Shares withheld for taxes
( 153
)
-
( 99
)
-
-
( 99
)
Stock-based compensation
-
-
1,396
-
-
1,396
Net loss
-
-
-
( 53,853
)
-
( 53,853
)
Other comprehensive loss
-
-
-
-
3,233
3,233
Balance at September 30, 2025
44,580
$
446
$
237,922
$
( 211,863
)
$
( 12,437
)
$
14,068
Accumulated
Number
Additional
Other
Total
of Shares
Common
Paid-in
Accumulated
Comprehensive
Stockholders’
Issued
Stock
Capital
Deficit
Loss
Equity
Balance at December 31, 2023
43,395
$
434
$
232,435
$
( 145,605
)
$
( 14,190
)
$
73,074
Stock option exercises
14
-
43
-
-
43
Stock purchase plan
72
1
175
-
-
176
Vesting of restricted stock units
150
1
-
-
-
1
Shares withheld for taxes
( 14
)
-
( 59
)
-
-
( 59
)
Stock-based compensation
-
-
3,379
-
-
3,379
Net loss
-
-
-
( 12,423
)
-
( 12,423
)
Other comprehensive income
-
-
-
-
1,131
1,131
Balance at September 30, 2024
43,617
436
235,973
( 158,028
)
( 13,059
)
65,322
See accompanying notes to condensed consolidated financial statements
4
Table of Contents
HARVARD BIOSCIENCE, INC.
Condensed Consolidated Statements Of Cash Flows
(Unaudited, in thousands)
Nine Months Ended September 30,
2025
2024
Cash flows from operating activities:
Net loss
$
( 53,853
)
$
( 12,423
)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation
1,287
1,268
Amortization of intangible assets
3,308
4,129
Goodwill impairment - Note 4
47,951
-
Amortization of deferred financing costs
698
229
Stock-based compensation
1,396
3,379
Deferred income taxes and other
( 553
)
( 361
)
Loss on equity securities - Note 6
-
1,593
Loss on pension settlement - Note 8
-
1,243
Changes in operating assets and liabilities:
Accounts receivable
3,022
3,303
Inventories
2,284
( 2,416
)
Other assets
421
873
Accounts payable and other liabilities
1,503
( 283
)
Contract liabilities
( 639
)
( 819
)
Net cash provided by (used in) operating activities
6,825
( 285
)
Cash flows from investing activities:
Additions to property, plant and equipment
( 809
)
( 2,343
)
Capitalized software development costs
( 455
)
( 454
)
Proceeds from sale of marketable equity securities
-
1,919
Net cash used in investing activities
( 1,264
)
( 878
)
Cash flows from financing activities:
Borrowing from revolving line of credit
-
8,800
Repayment of revolving line of credit
-
( 2,550
)
Repayment of term debt
( 3,000
)
( 5,023
)
Payment of debt issuance costs
( 687
)
( 161
)
Proceeds from exercise of stock options and employee stock purchase plan
46
219
Taxes paid related to net share settlement of equity awards
( 99
)
( 59
)
Net cash (used in) provided by financing activities
( 3,740
)
1,226
Effect of exchange rate changes on cash
888
223
Increase in cash and cash equivalents
2,709
286
Cash and cash equivalents at beginning of period
4,108
4,283
Cash and cash equivalents at end of period
$
6,817
$
4,569
Supplemental disclosures of cash flow information:
Cash paid for interest
$
2,549
$
2,369
Cash paid for income taxes, net of refunds
$
46
$
315
See accompanying notes to condensed consolidated financial statements
5
Table of Contents
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1.
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Summary of Significant Accounting Policies
The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, the “Company”) as of September 30, 2025, and for the three and nine months ended September 30, 2025 and 2024, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2024, consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of September 30, 2025, results of operations and comprehensive loss for the three and nine months ended September 30, 2025 and 2024, and cash flows for the nine months ended September 30, 2025 and 2024, as applicable, have been made. The results of operations for the three and nine months ended September 30, 2025, are not necessarily indicative of the anticipated operating results for the full year ending December 31, 2025, or any future periods.
The accounting policies underlying the accompanying condensed consolidated financial statements are set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes in the Company’s significant accounting policies during the nine months ended September 30, 2025.
Going Concern
The unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2025, have been prepared assuming that the Company will continue as a going concern. A going-concern basis assumes that the Company will continue its operations for the foreseeable future and contemplate the realization of assets and the settlement of liabilities in the normal course of business. As noted below, there is substantial doubt about the Company’s ability to continue as a going concern.
As of September 30, 2025, there was indebtedness of $ 34.0 million outstanding under the Company's term loan and senior revolving credit facility (collectively, the “Credit Agreement”). On August 8, 2025, the Company entered into an amendment (the “August 2025 Amendment”) to the Credit Agreement, pursuant to which the Lenders (defined below) and administrative agent agreed, subject to the terms contained in the August 2025 Amendment, to waive the events of default under the Credit Agreement due to the Company’s failure to achieve certain refinancing milestones (the “Refinancing Milestones”) and its failure to comply with certain financial covenants. In connection with the August 2025 Amendment, the Company has agreed to accomplish steps towards the refinancing (the “Refinancing”) or repayment of the Credit Agreement by no later than December 5, 2025. The Company continues to make progress on these steps, and is working actively to reach a definitive agreement that will accomplish one of these outcomes. The failure to accomplish such steps on the agreed timeline shall constitute an event of default under the Credit Agreement. In such event, in addition to other actions the lenders may require, the amounts outstanding under the Credit Agreement may become immediately due and payable.
The Company continues to explore alternative sources of capital that would allow it to refinance the outstanding indebtedness due under the Credit Agreement, but its ability to access such other sources of capital is uncertain. There is no assurance that such capital will be available, be obtainable on commercially acceptable terms, or provide the Company with sufficient funds to meet its objectives. Based on its anticipated cash flows from operations, unless the Company is able to access other sources of capital or extend the date for repayment under the Credit Agreement, the Company will be unable to pay its debt obligations and fund its operations for at least twelve months from the date of issuance of the condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q. As a result, there is substantial doubt about the Company's ability to continue as a going concern.
6
Table of Contents
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for income taxes, credit losses on receivables, and defined benefit pension obligations. Estimates are also required to assess the value for inventories reported at the lower of cost or net realizable value, stock-based compensation expense, and the recoverability of long-lived and intangible assets, including goodwill. On an ongoing basis, the Company assesses its previous estimates based upon currently available information. Actual results could differ materially from the estimates.
Other Operating Expenses
The components of other operating expenses for the three and nine months ended September 30, 2025 and 2024 were as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)
2025
2024
2025
2024
Employee retention tax credit fees (see Note 5)
$
-
$
-
$
341
$
472
Unclaimed property audits expense (see Note 13)
-
-
-
347
Restructuring expenses (see Note 14)
48
179
171
575
Total other operating expenses
$
48
$
179
$
512
$
1,394
Recently Issued Accounting Pronouncements Yet to Be Adopted
In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax (“ASU No. 2023-09”), which enhances disclosures related to the effective tax rate reconciliation, income taxes paid, as well as other disclosures. The new standard impacts footnote disclosures and is effective for the Company’s annual financial statements for the year ending December 31, 2025. The Company is continuing to assess the impact adopting ASU No. 2023-09 will have on the footnote disclosures in its consolidated financial statements.
In November 2024, the FASB issued ASU No. 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income — Expense Disaggregation Disclosures (“ASU No. 2024-03”), which requires enhanced disclosure of income statement expense categories to improve transparency and provide financial statement users with more detailed information about the nature, amount and timing of expenses impacting financial performance. This new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is continuing to assess the impact adopting ASU No. 2024-03 will have on the footnote disclosures in its consolidated financial statements.
In July 2025, the FASB issued ASU 2025-05, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU 2025-05”), requiring election of a practical expedient when estimating expected credit losses for current accounts receivable and current contract assets. ASU 2025-05 is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods. The Company is evaluating the impact that ASU 2025-05 will have on its consolidated financial statements.
2.
Earnings (Loss) per Share
Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted earnings (loss) per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive. The following table summarizes the calculation of basic and diluted net loss per share of common stock:
7
Table of Contents
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands, except per share data)
2025
2024
2025
2024
Net loss
$
( 1,231
)
$
( 4,802
)
$
( 53,853
)
$
( 12,423
)
Weighted average shares outstanding - basic
44,556
43,614
44,320
43,499
Dilutive effect of equity awards
-
-
-
-
Weighted average shares outstanding - diluted
44,556
43,614
44,320
43,499
Basic loss per share
$
( 0.03
)
$
( 0.11
)
$
( 1.22
)
$
( 0.29
)
Diluted loss per share
$
( 0.03
)
$
( 0.11
)
$
( 1.22
)
$
( 0.29
)
Shares excluded from diluted loss per share due to their anti-dilutive effect
2,666
3,988
2,523
3,730
3.
Revenues
The following tables represent a disaggregation of revenues from contracts with customers for the three and nine months ended September 30, 2025 and 2024:
Revenues by type were as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)
2025
2024
2025
2024
Instruments, equipment, software and accessories
$
18,582
$
20,543
$
56,625
$
64,594
Service, maintenance and warranty contracts
2,009
1,427
6,190
4,985
Total revenues
$
20,591
$
21,970
$
62,815
$
69,579
Revenues by timing of recognition were as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)
2025
2024
2025
2024
Goods and services transferred at a point in time
$
19,541
$
21,119
$
59,755
$
66,845
Goods and services transferred over time
1,050
851
3,060
2,734
Total revenues
$
20,591
$
21,970
$
62,815
$
69,579
Revenues by geographic region were as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)
2025
2024
2025
2024
Americas
United States
$
9,254
9,706
$
28,737
$
31,495
Americas - Other
1,185
1,211
2,436
2,635
Europe, Middle East and Africa
6,610
6,620
19,228
19,842
Asia
China
2,145
2,639
7,330
10,149
Asia - Other
1,397
1,794
5,084
5,458
$
20,591
$
21,970
$
62,815
$
69,579
8
Table of Contents
Contract Liabilities
The following table provides details of contract liabilities as of the periods indicated:
September 30,
December 31,
(in thousands)
2025
2024
Change
Percentage
Deferred revenue
Service, maintenance and warranty contracts
$
1,414
$
1,560
$
( 146
)
- 9
%
Installation and training
477
806
( 329
)
- 41
%
Customer advances
988
1,440
( 452
)
- 31
%
Total short-term contract liabilities
2,879
3,806
( 927
)
- 24
%
Long-term service, maintenance and warranty contracts
288
-
288
100
%
Total contract liabilities
$
3,167
$
3,806
$
( 639
)
- 17
%
Changes in the Company’s contract liabilities are primarily due to the timing of receipt of payments under service, maintenance and warranty contracts and lower sales volumes. Additionally, customer advances have decreased due to the recognition of amounts under the Company’s exchange program, which allows customers to purchase a replacement implantable monitor of the same model at a lower price than a new monitor if the customer returns an implantable monitor to the Company after use, and the returned monitor can be reprocessed and resold. During the three months ended September 30, 2025 and 2024, the Company recognized revenues of $ 0.4 million and $ 0.4 million from contract liabilities existing at December 31, 2024 and 2023, respectively. During the nine months ended September 30, 2025 and 2024, the Company recognized revenue of $ 3.2 million and $ 3.0 million from contract liabilities existing at December 31, 2024 and 2023, respectively.
The following table represents the Company's remaining performance obligations from contracts that are recognized over time as of September 30, 2025:
Remaining Performance Obligations
(in thousands)
2025 *
2026
2027
2028
2029
Thereafter
Total
Service, maintenance and warranty contracts
$
1,194
$
450
$
38
$
15
$
5
$
-
$
1,702
* remainder of the year
Provision for Expected Credit Losses on Receivables
Activity in the provision for expected credit losses on receivables was as follows:
Nine Months Ended September 30,
(in thousands)
2025
2024
Balance, beginning of period
$
215
$
160
Provision for expected credit losses
( 29
)
13
Charge-offs and other
( 24
)
1
Balance, end of period
$
162
$
174
Concentrations
No customer accounted for more than 10% of revenues for the three and nine months ended September 30, 2025 and 2024. At September 30, 2025 and December 31, 2024, no customer accounted for more than 10% of net accounts receivable.
9
Table of Contents
Warranties
Activity in the product warranties accrual was as follows:
Nine Months Ended September 30,
(in thousands)
2025
2024
Balance, beginning of period
$
318
$
336
Provision for warranties
131
307
Warranty claims
( 145
)
( 228
)
Balance, end of period
$
304
$
415
4.
Goodwill and Long-Lived Assets
The Company determined that a sustained decrease in its stock price that occurred during the three months ended March 31, 2025 indicated that the carrying values of its goodwill and other long-lived assets may not be recoverable. Additional factors that contributed to this conclusion are the Company’s recent operating results, liquidity risk and the current macroeconomic conditions impacting the life sciences industry. Based on this determination, the Company performed interim quantitative impairment tests on its goodwill and other long-lived assets as of March 31, 2025 and June 30, 2025, as well as a qualitative analysis as of September 30, 2025.
The recoverability of assets or an asset group to be held and used is measured by a comparison of the carrying amount of an asset or asset group to estimated undiscounted future cash flows expected to be generated by the asset or the asset group. Based on its recoverability assessment, the Company determined that there was no impairment of its other long-lived assets as of March 31, 2025 and June 30, 2025. Based on its qualitative analysis the Company determined that there was no impairment of its other long-lived assets as of September 30, 2025.
For the purpose of its goodwill impairment analysis, the Company has one reporting unit. The Company estimated the fair value of the reporting unit using an income-based valuation approach by means of a discounted cash flow (“DCF”) model. Under this model, the fair value of the reporting unit is determined based on the present value of estimated future cash flows, discounted at a risk-adjusted rate of return. The Company used internal forecasts and strategic long-term plans to estimate future cash flows, including projections of revenue and EBITDA, capital expenditure and working capital requirements, terminal growth rates, statutory tax rates and a market-participant discount rate. The goodwill impairment analysis also includes a reconciliation of the aggregate estimated fair value of the reporting unit to the Company’s total market capitalization. Based on this quantitative impairment analysis as of March 31, 2025, the Company determined that the carrying value of the reporting unit exceeded its fair value by $ 48.0 million. Accordingly, the Company recorded such amount as a goodwill impairment charge for the three months ended March 31, 2025. Based on the quantitative impairment analysis performed as of June 30, 2025 and qualitative analysis performed as of September 30, 2025, an additional impairment charge was not required during the three months ended June 30, 2025, and September 30, 2025.
The inputs and assumptions used in determining the fair value of the reporting unit are subjective and require management’s use of significant judgment. Certain future events and circumstances, including further deterioration of the Company’s stock price, operating results, and macroeconomic conditions, and a higher cost of capital, among others, could result in changes to these inputs and assumptions. A revision of these inputs and assumptions could cause the fair value of the reporting unit to fall further below its carrying value, resulting in additional impairment charges, which could have a material adverse effect on the Company’s results of operations.
The change in the carrying amount of goodwill for the nine months ended September 30, 2025 was as follows:
(in thousands)
Carrying amount at December 31, 2024
$
56,324
Goodwill impairment
( 47,951
)
Effect of change in currency translation
1,152
Carrying amount at September 30, 2025
$
9,525
10
Table of Contents
Intangible assets, net at September 30, 2025 and December 31, 2024 consisted of the following:
September 30, 2025
December 31, 2024
(in thousands)
Accumulated
Accumulated
Amortizable intangible assets:
Gross
Amortization
Net
Gross
Amortization
Net
Customer relationships
$
16,318
$
( 11,818
)
$
4,500
$
15,603
$
( 10,450
)
$
5,153
Technology and software development
36,231
( 33,229
)
3,002
35,397
( 30,556
)
4,841
Trade names and patents
7,708
( 7,049
)
659
7,452
( 6,509
)
943
Total amortizable intangible assets
$
60,257
$
( 52,096
)
$
8,161
$
58,452
$
( 47,515
)
$
10,937
Indefinite-lived intangible assets:
218
195
Total intangible assets
$
8,379
$
11,132
Intangible asset amortization expense for the three and nine months ended September 30, 2025 and 2024 was as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)
2025
2024
2025
2024
Cost of revenues
$
44
$
44
$
131
$
131
Operating expense
855
1,334
3,177
3,998
Total amortization of intangible assets
$
899
$
1,378
$
3,308
$
4,129
As of September 30, 2025, estimated future amortization expense of amortizable intangible assets is as follows:
(in thousands)
2025 (remainder of year)
$
894
2026
2,904
2027
1,632
2028
1,385
2029
949
Thereafter
397
Total
$
8,161
5.
Balance Sheet Information
The following tables provide details of selected balance sheet items as of the periods indicated:
Inventories:
September 30,
December 31,
(in thousands)
2025
2024
Finished goods
$
5,863
$
5,222
Work in process
2,256
2,754
Raw materials
13,485
15,269
Total
$
21,604
$
23,245
11
Table of Contents
Other Current Liabilities:
September 30,
December 31,
(in thousands)
2025
2024
Compensation
$
1,871
$
1,714
Customer credits
1,225
1,286
Current portion of operating lease liabilities
1,486
1,158
Employee retention tax credit funds
5,420
3,154
Professional fees
465
545
Warranty costs
304
318
Other
1,603
1,234
Total
$
12,374
$
9,409
The Coronavirus Aid, Relief, and Economic Security Act of 2020 (the “CARES Act”) provided an employee retention tax credit (“ERTC”) that was a refundable tax credit against certain employer taxes. The Company elected to account for the credit as a government grant. As there is no authoritative guidance under U.S. GAAP on accounting for grants to for-profit business entities from government entities, the Company accounts for government assistance by applying the principles of International Accounting Standards Topic 20, Accounting for Government Grants and Disclosure of Government Assistance (“IAS 20”). Under IAS 20, government grants are recognized when there is reasonable assurance that the grant will be received and that all conditions related to the grant will be met.
The Company received ERTC refunds of $ 2.2 million and $ 3.2 million during the nine months ended September 30, 2025 and 2024, respectively. The Company has included the refunds received in other current liabilities in the consolidated balance sheets as of September 30, 2025 and 2024, subject to a determination that the refunds are recognizable.
The Company engaged a professional services firm under a commission fee arrangement to assist with determining the Company’s eligibility to claim the ERTC refunds and accumulating the necessary support that was used as a basis in the filing. The Company paid fees of $ 0.3 million and $ 0.5 million during the nine months September 30, 2025 and 2024, respectively, for these services, which are included in other operating expenses in the consolidated statement of operations.
6.
Marketable Equity Securities
In April 2023, the Company received shares of common stock of Harvard Apparatus Regenerative Technology, Inc. (“HRGN”, formerly known as Biostage, Inc.) in connection with settlement of indemnification obligations related to litigation which was resolved during the year ended December 31, 2022.
During the nine months ended September 30, 2024, the Company sold all of its remaining HRGN shares. The Company received cash proceeds of $ 1.4 million and $ 1.9 million from HRGN shares sold during the three and nine months ended September 30, 2024, respectively. The Company recorded losses on equity securities of $ 0.3 million and $ 1.6 million during the three and nine months ended September 30, 2024, respectively. The Company determined the fair value of its HRGN common stock based on the closing price as quoted on the OTCQB Marketplace at the reporting date. The Company did not hold any shares of HRGN stock during the nine months ended September 30, 2025.
7.
Leases
The Company has noncancelable operating leases for offices, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2030.
The components of lease expense for the three and nine months ended September 30, 2025 and 2024, were as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)
2025
2024
2025
2024
Operating lease cost
$
563
$
520
$
1,610
$
1,539
Short-term lease cost
45
46
133
148
Sublease income
-
( 17
)
-
( 68
)
Total lease cost
$
608
$
549
$
1,743
$
1,619
12
Table of Contents
Supplemental cash flow information related to the Company's operating leases is as follows:
Nine Months Ended September 30,
(in thousands)
2025
2024
Cash paid for amounts included in the measurement of lease liabilities
$
1,776
$
1,745
Right-of-use assets obtained in exchange for lease obligations
2,246
2,945
Supplemental balance sheet information related to the Company’s operating leases is as follows:
September 30,
December 31,
(in thousands)
2025
2024
Operating lease right-of-use assets
$
7,500
$
6,132
Current portion, operating lease liabilities
$
1,486
$
1,158
Operating lease liabilities, long-term
7,332
6,381
Total operating lease liabilities
$
8,818
$
7,539
Weighted average remaining lease term (years)
4.4
5.2
Weighted average discount rate
7.9
%
8.9
%
Future minimum lease payments for operating leases, with initial terms in excess of one year at September 30, 2025, are as follows:
Year Ending December 31,
(in thousands)
2025 (remainder of the year)
$
522
2026
2,423
2027
2,394
2028
2,310
2029
2,071
Thereafter
870
Total lease payments
10,590
Less imputed interest
( 1,772
)
Total operating lease liabilities
$
8,818
8.
Debt
The Company’s debt, which was included within current liabilities as of September 30, 2025 and December 31, 2024, was as follows:
(in thousands)
September 30, 2025
December 31, 2024
Term loan
$
21,700
$
24,700
Revolving line
12,650
12,650
Less: unamortized deferred financing costs
( 383
)
( 394
)
Total debt
$
33,967
$
36,956
13
Table of Contents
The Company maintains a Credit Agreement with Citizens Bank, N.A., Wells Fargo Bank, N.A., and First-Citizens Bank & Trust Company (the “Lenders”). The Credit Agreement originally provided for a term loan of $ 40.0 million and a $ 25.0 million revolving credit facility (including a $ 10.0 million sub-facility for the issuance of letters of credit and a $ 10.0 million swingline loan sub facility) (collectively, the “Credit Facility”). The Company’s obligations under the Credit Agreement are secured by substantially all of its assets, including all or a portion of the equity interests in certain of the Company’s domestic and foreign subsidiaries. The Company’s obligations under the Credit Agreement are guaranteed by certain of the Company’s direct, domestic wholly owned subsidiaries; none of the Company’s direct or indirect foreign subsidiaries has guaranteed the Company’s obligations under the Credit Agreement. Issuance costs of $ 2.0 million are amortized over the contractual term to maturity date on a straight-line basis, which approximates the effective interest method. Total revolver borrowing capacity is limited by the consolidated net leverage ratio as defined under the amended Credit Agreement. As of the date of these financial statements, the Company was unable to make additional borrowings under its revolving credit facility due to net leverage ratio requirements set forth in the August 6, 2024 amendment to the Credit Agreement and the terms of the March 10, 2025 amendment to the Credit Agreement (the “March 2025 Amendment”), as described below.
Borrowings under the Credit Facility, at the option of the Company, bear interest at either (i) a rate per annum based on the Secured Overnight Financing Rate (“SOFR”) for an interest period of one, two, three or six months, plus an applicable interest rate margin determined as provided in the Credit Agreement (a “SOFR Loan”), subject to a floor of 0.50 %, or (ii) an alternative base rate plus an applicable interest rate margin, each as determined as provided in the Credit Agreement. The alternative base rate is based on the Citizens Bank prime rate or the federal funds effective rate of the Federal Reserve Bank of New York and is subject to a floor of 1.0 %. Pursuant to the March 2025 Amendment, the applicable interest rate margin was increased such that interest rate was equal to a rate per annum based on the SOFR plus 400 bps effective as of March 10, 2025. There are no prepayment penalties in the event the Company elects to prepay and terminate the Credit Facility prior to its scheduled maturity date, subject to SOFR Loan breakage and redeployment costs in certain circumstances.
The effective interest rate on the Company’s borrowings for the three months ended September 30, 2025 and 2024, was 11.0 % and 8.7 %, respectively, and for the nine months ended September 30, 2025 and 2024 was 9.4 % and 8.1 %, respectively. The weighted average interest rate as of September 30, 2025, net of the effect of the Company’s interest rate swap agreement, was 10.0 %. The carrying value of the debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments.
The term loan required quarterly installment payments of $ 1.0 million with a balloon payment at maturity on December 22, 2025. Pursuant to the March 2025 Amendment, amortization payments were revised so that a proportionate payment must be made on a monthly rather than a quarterly basis.
The Credit Agreement includes various customary financial covenants and other affirmative and negative covenants binding on the Company. The negative covenants limit the ability of the Company, among other things, to incur debt, permit liens, make investments, sell assets, or pay dividends on its capital stock. The financial covenants include a maximum consolidated net leverage ratio and a minimum consolidated fixed charge coverage ratio. The Credit Agreement also includes customary events of default.
The March 2025 Amendment provided, among other things, that the Lenders’ commitment under the revolving credit facility would be capped at $ 12.65 million, which was the amount outstanding thereunder as of the date thereof, and thus we are unable to make additional borrowings under our revolving credit facility. The March 2025 Amendment also established certain Refinancing Milestones in connection with the Refinancing, including, by June 30, 2025, the closing of the Refinancing. The Lenders also agreed not to assert any breaches of the financial covenants included in the Credit Agreement for the first quarter of 2025 provided that the Company continued to comply with its payment obligations, achieved the Refinancing Milestones, maintained minimum liquidity (defined as the sum of (a) unrestricted cash and cash equivalents and (b) the amount by which the aggregate amount committed under the Company’s revolving credit facility exceeds the total amount drawn under the credit facility) of $ 3.5 million and provided the administrative agent with certain financial reports.
As of June 30, 2025, the Company was not in compliance with the Refinancing Milestones and quarterly financial covenants included in the March 2025 Amendment. On August 8, 2025, the Company entered into the August 2025 Amendment, pursuant to which the Lenders and administrative agent agreed, subject to the terms contained in the August 2025 Amendment, to waive the events of default due to the Company’s failure to achieve certain Refinancing Milestones and its failure to comply with the consolidated net leverage ratio covenant and the consolidated fixed charge coverage ratio covenant as of the June 30, 2025 test date. Pursuant to the terms of the August 2025 Amendment, the Lenders also agreed not to test the net leverage ratio financial covenant and the consolidated fixed charge coverage ratio financial covenant for the fiscal quarter ended September 30, 2025, and to reduce the Company’s covenant to maintain minimum liquidity (defined as the sum of (a) unrestricted cash and (b) the amount by which the aggregate amount committed under the Company’s revolving credit facility exceeds the total amount drawn under the credit facility) of $ 3.0 million.
14
Table of Contents
The August 2025 Amendment also added, as a mandatory prepayment event, the receipt of cash proceeds upon a Refinancing or upon the sale of the equity interests or all or substantially all of the assets of the Company. In addition, pursuant to the terms of the August 2025 Amendment, the applicable interest rate margin was increased such that the interest rate is equal to a rate per annum based on the SOFR plus 700 bps. In connection with the August 2025 Amendment, the Company has agreed to accomplish steps towards the Refinancing or repayment of the Credit Agreement by no later than December 5, 2025. The Company continues to make progress on these steps, and is working actively to reach a definitive agreement that will accomplish one of these outcomes. The failure to accomplish such steps on the agreed timeline shall constitute an event of default under the Credit Agreement.
The Company agreed to pay fees of $ 0.4 million, or 1.00 % of the outstanding debt, to the Lenders in connection with the August 2025 Amendment, of which 25% was paid upon the signing of the August 2025 Amendment and the remaining 75% will be payable upon a Refinancing or repayment of the Credit Agreement or upon the occurrence of an event of default.
9.
Derivatives
In February 2023, the Company entered into an interest rate swap contract to improve the predictability of cash flows from interest payments related to its variable, SOFR-based debt. The swap contract had a notional amount of $ 17.6 million as of September 30, 2025 and matures on December 22, 2025. This swap contract effectively converts the SOFR-based variable portion of the interest payable under the Credit Agreement into fixed-rate debt at an annual rate of 4.75 %. The swap contract does not impact the additional interest related to the applicable interest rate margin as discussed above in Note 8, Debt.
The swap contract is considered an effective cash flow hedge, and as a result, net gains or losses are reported as a component of other comprehensive income (“OCI”) in the consolidated financial statements and are reclassified when the underlying hedged interest impacts earnings. An assessment is performed quarterly to evaluate the ongoing hedge effectiveness.
The following table presents the notional amount and fair value of the Company’s derivative instruments as of September 30, 2025 and December 31, 2024:
(in thousands)
September 30, 2025
December 31, 2024
Derivatives Instruments
Balance Sheet Classification
Notional Amount
Fair Value (a)
Notional Amount
Fair Value (a)
Interest rate swap
Other current liabilities
$
17,550
$
( 27
)
$
21,658
$
( 99
)
(a) See Note 10 for the fair value measurements related to these financial instruments.
The effect of the cash flow hedge on other comprehensive income (loss) and earnings for the periods presented was as follows:
Three Months Ended September 30,
Nine Months Ended September 30, 2025
Derivatives Qualifying as Hedges, net of tax (in thousands)
2025
2024
2025
2024
Gain (loss) recognized in OCI on derivatives (effective portion)
$
18
$
( 257
)
$
72
$
( 24
)
Amounts reclassified from AOCI to interest expense
( 16
)
42
( 50
)
133
10.
Fair Value Measurements
The following tables present the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis:
Fair Value as of September 30, 2025
Assets (Liabilities) (in thousands)
Level 1
Level 2
Level 3
Total
Interest rate swap agreement
$
-
$
( 27
)
$
-
$
( 27
)
Fair Value as of December 31, 2024
Level 1
Level 2
Level 3
Total
Interest rate swap agreement
$
-
$
( 99
)
$
-
$
( 99
)
15
Table of Contents
The Company uses the market approach technique to value its financial liabilities. The fair value of the Company’s interest rate swap agreement was based on SOFR yield curves at the reporting date and is included within other current liabilities on the consolidated balance sheets at both September 30, 2025 and December 31, 2024.
11.
Stock-Based Compensation
Stock-based compensation expense for the three and nine months ended September 30, 2025 and 2024 was allocated as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)
2025
2024
2025
2024
Cost of revenues
$
18
$
( 30
)
$
79
$
88
Sales and marketing expenses
122
164
346
453
General and administrative expenses
104
795
703
2,493
Research and development expenses
80
124
268
345
Total stock-based compensation
$
324
$
1,053
$
1,396
$
3,379
As of September 30, 2025, the total compensation costs related to unvested awards not yet recognized was $ 1.8 million and the weighted average period over which such costs are expected to be recognized is approximately 1.7 years. The Company did not capitalize any stock-based compensation.
Restricted stock unit (“RSU”) activity for the nine months ended September 30, 2025 was as follows:
Market-
Performance-
Time-Based
Based
Based
Restricted
Grant Date
Restricted
Grant Date
Restricted
Grant Date
Stock Units
Fair Value
Stock Units
Fair Value
Stock Units
Fair Value
Balance at December 31, 2024
1,378,995
$
3.51
558,958
$
2.61
375,895
$
4.19
Granted
1,237,821
0.45
500,000
0.67
-
-
Vested
( 536,145
)
3.57
-
-
-
-
Forfeited
( 369,499
)
3.56
( 192,473
)
2.61
( 211,815
)
4.19
Balance at September 30, 2025
1,711,172
$
1.27
866,485
$
1.49
164,080
$
4.19
The aggregate fair value of RSUs that vested during the nine months ended September 30, 2025, and 2024 was $ 0.3 million and $ 0.5 million, respectively. Unvested shares related to market-based and performance-based vesting conditions are reflected at 100% of their target vesting amount in the table above. Actual vesting could range from zero to 150 % of their target amounts.
Performance-based RSU awards are contingent on the achievement of certain performance metrics. Compensation cost associated with performance-based RSUs are recognized based on the estimated number of shares that the Company ultimately expects will be earned. If the estimated number of shares to be earned is revised in the future, then stock-based compensation expense will be adjusted accordingly.
The weighted average estimated fair value of the market condition restricted stock awards that were granted during the nine months ended September 30, 2025 was $0.67 per unit. The estimate of the fair value was determined using a Monte-Carlo valuation simulation, which included the following assumptions:
Volatility
89.8
%
Risk-free interest rate
3.7
%
Correlation coefficient
36.5
%
Dividend yield
-
%
Stock option activity for the nine months ended September 30, 2025 was as follows:
16
Table of Contents
Number of Options
Weighted-Average Exercise Price
Weighted-Average Remaining Contractual Term
Aggregate Intrinsic Value (in thousands)
Outstanding and exercisable at December 31, 2024
827,458
$
3.24
Cancelled/Forfeited
( 660,755
)
3.20
Outstanding and exercisable at September 30, 2025
166,703
$
3.39
2.4
$
-
There is no aggregate intrinsic value at September 30, 2025 because the Company’s closing stock price of $ 0.44 is below the exercise price of the outstanding options.
12.
Income Tax
The determination of the annual effective tax rate is based upon a number of significant estimates and judgments, including the estimated annual pretax income in each tax jurisdiction in which the Company operates and the development of tax planning strategies during the year. In addition, as a global commercial enterprise, the Company’s tax expense can be impacted by changes in tax rates or laws, the finalization of tax audits and reviews and other factors that cannot be predicted with certainty. As such, there can be significant volatility in interim tax provisions.
Income tax expense (benefit) was $ 0.1 million and $ 0.3 million for the three months ended September 30, 2025 and 2024, respectively, and was ($ 0.3 ) million and $ 0.2 million for the nine months ended September 30, 2025 and 2024, respectively. The Company’s effective tax rate of ( 8.6 )% and 0.6 % for the three and nine months ended September 30, 2025, respectively, were lower than the U.S statutory rate due to the tax effect of goodwill impairment. The Company’s effective tax rates of ( 6.9 )% and ( 1.4 )% for the three and nine months ended September 30, 2024, respectively, were different than the U.S. statutory rate primarily due to the inclusion of non-deductible executive compensation. The effective tax rate for both periods was also impacted by changes in valuation allowances associated with the Company’s assessment of the likelihood of the recoverability of deferred tax assets.
On July 4, 2025, subsequent to the end of the second quarter of fiscal 2025, the One Big Beautiful Bill Act (the “Act”) was signed into law. The Act includes several significant tax-related provisions, including the permanent extension of certain elements of the Tax Cuts and Jobs Act. The legislation features staggered effective dates beginning in 2025 and continuing through 2027. The Company has incorporated the provisions from the Act into the Q3 2025 income tax provision and has concluded that these changes did not have a significant impact on its consolidated financial statements and related disclosures.
13.
Commitments and Contingent Liabilities
The Company is occasionally subject to claims and lawsuits which typically arise in the normal course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe that the outcome of any of these legal matters will have a material adverse effect on the Company’s business, results of operations, financial condition, or cash flows.
The Company is subject to unclaimed property laws in the ordinary course of its business. State escheat laws generally require entities to report and remit abandoned and unclaimed property to the state. Failure to timely report and remit the property can result in assessments that could include interest and penalties, in addition to the payment of the escheat liability itself. The Company recorded an expense of $ 0.3 million during the nine months ended September 30, 2024 related to unclaimed property audits which have been included in other operating expenses in the consolidated statement of operations. The unclaimed property audit was completed during the second quarter of fiscal 2024.
14.
Restructuring Costs
On an ongoing basis, the Company reviews the global economy, the life sciences industry, and the markets in which it competes to identify operational efficiencies and align its cost base and infrastructure with customer needs and its strategic plans. In order to achieve these goals, the Company undertakes activities from time to time to optimize its business.
17
Table of Contents
During the nine months ended September 30, 2025, the Company initiated additional restructurings for which it incurred $ 0.2 million of costs, primarily consisting of severance incurred in connection with headcount reductions in North America and Europe. The Company expects the restructuring to be completed during the year ending December 31, 2025.
During the nine months ended September 30, 2024, the Company completed a restructuring and incurred expenses of $ 0.6 million, primarily consisting of severance incurred in connection with headcount reductions in North America and Europe. Severance and other costs have been included as a component of other operating expenses (see Note 1). The changes in the accrued liability for restructuring and other charges for the nine months ended September 30, 2025 were as follows:
(in thousands)
Severance
Balance at December 31, 2024
$
82
Restructuring costs
171
Cash payments
( 178
)
Effect of change in currency translation
4
Balance at September 30, 2025
$
79
15.
Segment Information
The Company conducts business as a single operating segment, which is based upon the Company’s organizational and management structure, as well as information used by the chief operating decision maker (“CODM”) to allocate resources and other factors. The key measure of segment profitability that the CODM uses to allocate resources and assess performance is consolidated net income (loss), as reported on the consolidated statements of operations. The CODM utilizes consolidated net loss by comparing actual results against budgeted amounts on a quarterly basis. The following table presents the significant revenue and expense categories of the Company’s single operating segment:
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Revenues
$
20,591
$
21,970
$
62,815
$
69,579
Less:
Cost of revenues (1)
8,552
9,235
26,998
28,736
Sales and marketing expenses (1)
4,491
5,354
13,777
16,364
General and administrative expenses (1)
4,072
4,246
12,920
14,197
Research and development expenses (1)
2,052
2,443
6,374
7,733
Amortization of acquired intangibles
855
1,334
3,177
3,998
Interest expense
966
856
2,559
2,356
Loss on pension settlement
-
1,243
-
1,243
Income tax expense (benefit)
97
311
( 329
)
168
Goodwill impairment
-
-
47,951
-
Other segment expenses (2)
737
1,750
3,241
7,207
Net loss
$
( 1,231
)
$
( 4,802
)
$
( 53,853
)
$
( 12,423
)
(1) Excludes stock-based compensation expense
(2) Includes stock-based compensation, other operating expenses, loss on equity securities and other expenses
Asset information provided to the CODM is consistent with that reported on the consolidated balance sheets with particular emphasis on the Company’s available liquidity, including its cash, accounts receivable, and inventory, reduced by current liabilities. Information relating to the Company’s products and services and geographical distribution of revenues is disclosed in Note 3.
18
Table of Contents
Item 2. Management ’ s Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “ Exchange Act ” ). The forward-looking statements are principally, but not exclusively, contained in “ Item 2: Management ’ s Discussion and Analysis of Financial Condition and Results of Operations. ” These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management ’ s confidence or expectations, and our plans, objectives, expectations, and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “ may, ” “ will, ” “ should, ” “ could, ” “ would, ” “ seek, ” “ expects, ” “ plans, ” “ aim, ” “ anticipates, ” “ believes, ” “ estimates, ” “ is likely, ” “ projects, ” “ forecasts, ” “ predicts, ” “ intends, ” “ think, ” “ potential, ” “ objectives, ” “ optimistic, ” “ strategy, ” “ goals, ” “ sees, ” “ new, ” “ guidance, ” “ future, ” “ continue, ” “ drive, ” “ growth, ” “ long-term, ” “ projects, ” “ develop, ” “ possible, ” “ emerging, ” “ opportunity, ” “ pursue ” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in detail in our Annual Report on Form 10-K for the year ended December 31, 2024 and our other filings with the SEC. You should carefully review all of these factors, as well as other risks described in our public filings, and you should be aware that there may be other factors, including factors of which we are not currently aware, that could cause these differences. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. Harvard Bioscience, Inc. is referred to herein as “ we, ” “ our, ” “ us, ” and “ the Company. ”
Overview
Harvard Bioscience, Inc., a Delaware corporation, is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Our products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations (“CROs”). With operations in the United States, Europe and China, we sell through a combination of direct and distribution channels to customers around the world.
Trends and Developments
Our business is affected by global and regional economic trends and uncertainties. Our revenue has been and may continue to be affected by our customers forgoing or delaying purchases of our products and services as a result of ongoing uncertainty with respect to the level and timing of funding from the U.S. National Institutes of Health (the “NIH”) or similar government sources. Our business has also been affected by the imposition of increased tariffs on shipments of products between the United States and other countries, and in particular between the United States and China. Our revenue has been and may continue to be affected by greater restrictions and economic disincentives on international trade, including these tariffs. Products and services that we obtain from overseas sources have been and may continue to be affected by these tariffs, resulting in increased costs to our business.
If these trends are prolonged or are more severe than anticipated, our business, results of operations, and cash flow may be materially impacted.
As of June 30, 2025, the Company was not in compliance with certain refinancing milestones (the “Refinancing Milestones”) and quarterly financial covenants contained in the Company's term loan and senior revolving credit facility, dated as of December 22, 2020 (collectively, as amended, the “Credit Agreement”). On August 8, 2025, the Company entered into an amendment to the Credit Agreement (the “August 2025 Amendment”), pursuant to which the lenders party to the Credit Agreement (the “Lenders”) and the administrative agent agreed to waive the events of default due to the Company’s failure to achieve the Refinancing Milestones and its failure to comply with the consolidated net leverage ratio covenant and the consolidated fixed charge coverage ratio covenant as of the June 30, 2025 test date. See “Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources” of this report for additional information.
19
Table of Contents
Selected Results of Operations
Three months ended September 30, 2025, compared to three months ended September 30, 2024
Three Months Ended September 30,
(dollars in thousands)
2025
% of revenue
2024
% of revenue
Revenues
$
20,591
$
21,970
Gross profit
12,021
58.4
%
12,765
58.1
%
Sales and marketing expenses
4,613
22.4
%
5,518
25.1
%
General and administrative expenses
4,176
20.3
%
5,041
22.9
%
Research and development expenses
2,132
10.4
%
2,567
11.7
%
Amortization of intangible assets
855
4.2
%
1,334
6.1
%
Other operating expenses
48
0.2
%
179
0.8
%
Interest expense
966
4.7
%
856
3.9
%
Loss on pension settlement
-
0.0
%
1,243
5.7
%
Income tax expense
97
0.5
%
311
1.4
%
Revenues
Revenues decreased $1.4 million, or 6.3%, to $20.6 million for the three months ended September 30, 2025, compared to $22.0 million for the three months ended September 30, 2024. The decrease in revenues was primarily due to the continued softening of worldwide demand primarily from academic research institutions and CROs and the impact of reciprocal tariffs.
Gross profit
Gross profit decreased $0.8 million, or 5.8%, to $12.0 million for the three months ended September 30, 2025, compared with $12.8 million for the three months ended September 30, 2024, primarily due to the decrease in revenues as well as the associated lower absorption of fixed manufacturing costs. Gross margin was 58.4% for the three months ended September 30, 2025, compared to 58.1% for the three months ending September 30, 2024. The increase in gross margin was primarily due to favorable product mix.
Sales and marketing expenses
Sales and marketing expenses decreased $0.9 million, or 16.4%, to $4.6 million for the three months ended September 30, 2025, compared with $5.5 million for the three months ended September 30, 2024. This decrease was primarily due to reduced compensation, travel and entertainment, and trade show expenses.
General and administrative expenses
General and administrative expenses decreased $0.8 million, or 17.2%, to $4.2 million for the three months ended September 30, 2025, compared with $5.0 million for the three months ended September 30, 2024. The decrease was primarily due to reduced compensation costs.
Research and development expenses
Research and development expenses decreased $0.5 million, or 16.9%, to $2.1 million for the three months ended September 30, 2025, compared with $2.6 million for the three months ended September 30, 2024. This decrease was primarily due to reduced compensation costs.
Amortization of intangible assets
Amortization of intangible assets included in operating expenses was $0.9 million for the three months ended September 30, 2025, compared with $1.3 million for the three months ended September 30, 2024.
Other operating expenses
Other operating expenses for the three months ended September 30, 2024 were $0.2, which consisted of restructuring costs in connection with headcount reductions in Europe and North America.
20
Table of Contents
Interest expense
Interest expense was $1.0 million for the three months ended September 30, 2025, compared with $0.9 million for the three months ended September 30, 2024.
Loss on pension settlement
During the three months ended September 30, 2024, we settled our obligations under one of our defined benefit plans by using plan assets to purchase non-participating annuity contracts. The settlement resulted in the recognition of a non-cash charge of $1.2 million, which has been presented as a component of other income (expense), net. This amount includes the immediate recognition of the portion of the accumulated other comprehensive income (“AOCI”) balance related to this plan.
Income tax expense (benefit)
The income tax expense (benefit) was $0.1 million and $0.3 million for the three months ended September 30, 2025 and 2024, respectively. The effective tax rates for the three months ended September 30, 2025 and 2024 were (8.6)% and (6.9)%, respectively. The higher effective tax rate during the three months ended September 30, 2025, compared to the three months ended September 30, 2024, was primarily due to the change in the mix of income by jurisdiction. The Company’s effective tax rate for the three months ended September 30, 2025, was different than the U.S. statutory rate primarily due to a Global Intangible Low-Tax Income (“GILTI”) inclusion to taxable income, and changes in valuation allowances associated with the Company’s assessment of the likelihood of the recoverability of deferred tax assets.
Nine months ended September 30, 2025, compared to nine months ended September 30, 2024
Nine Months Ended September 30,
(dollars in thousands)
2025
% of revenue
2024
% of revenue
Revenues
$
62,815
$
69,579
Gross profit
35,738
56.9
%
40,755
58.6
%
Sales and marketing expenses
14,123
22.5
%
16,817
24.2
%
General and administrative expenses
13,623
21.7
%
16,690
24.0
%
Research and development expenses
6,642
10.6
%
8,078
11.6
%
Amortization of intangible assets
3,177
5.1
%
3,998
5.7
%
Goodwill impairment
47,951
76.3
%
-
0.0
%
Other operating expenses
512
0.8
%
1,394
2.0
%
Interest expense
2,559
4.1
%
2,356
3.4
%
Loss on pension settlement
-
0.0
%
1,243
1.8
%
Loss on equity securities
-
0.0
%
1,593
2.3
%
Income tax (benefit) expense
(329
)
-0.5
%
168
0.2
%
Revenues
Revenues decreased $6.8 million, or 9.7%, to $62.8 million for the nine months ended September 30, 2025, compared to $69.6 million for the nine months ended September 30, 2024. The decrease in revenues was primarily due to the continued softening of worldwide demand primarily from academic research institutions and CROs and the impact of reciprocal tariffs.
Gross profit
Gross profit decreased $5.1 million, or 12.3%, to $35.7 million for the nine months ended September 30, 2025, compared with $40.8 million for the nine months ended September 30, 2024, primarily due to the decrease in revenues as well as the associated lower absorption of fixed manufacturing costs. Gross margin decreased to 56.9% for the nine months ended September 30, 2025, compared with 58.6% for the nine months ended September 30, 2024. The decrease in gross margin was primarily the result of under-absorption of fixed manufacturing overhead costs due to the decrease in revenues, increases in purchase price variance as well as a higher mix of lower margin products.
21
Table of Contents
Sales and marketing expenses
Sales and marketing expenses decreased $2.7 million, or 16.0%, to $14.1 million for the nine months ended September 30, 2025, compared with $16.8 million for the nine months ended September 30, 2024. This decrease was primarily due to reduced compensation, travel and entertainment, and trade show expenses.
General and administrative expenses
General and administrative expenses decreased $3.1 million, or 18.4%, to $13.6 million for the nine months ended September 30, 2025, compared with $16.7 million for the nine months ended September 30, 2024. The decrease was primarily due to reduced compensation costs, partially offset by an increase of $0.2 million in audit and legal fees.
Research and development expenses
Research and development expenses decreased $1.5 million, or 17.8%, to $6.6 million for the nine months ended September 30, 2025, compared with $8.1 million for the nine months ended September 30, 2024. This decrease was primarily due to reduced compensation costs.
Amortization of intangible assets
Amortization of intangible assets included in operating expenses decreased $0.8 million, or 20.5%, to $3.2 million for the nine months ended September 30, 2025, compared with $4.0 million for the nine months ended September 30, 2024.
Goodwill impairment
Goodwill impairment expenses increase by $48.0 million for the nine months ended September 30, 2025. We identified a triggering event, including the sustained decrease in our stock price, our recent operating results, liquidity risk and the current macroeconomic conditions impacting the life sciences industry, requiring an interim impairment test. We recorded a non-cash goodwill impairment charge of $48.0 million in connection with the interim impairment test.
Other operating expenses
Other operating expenses decreased by $0.9 million, or 63.3% to $0.5 million for the nine months ended September 30, 2025, compared to $1.4 million for the nine months ended September 30, 2024. Other operating expenses for the nine months ended September 30, 2025, included a fee of $0.3 million in connection with the receipt of employee retention credits and restructuring costs of $0.2 million in connection with headcount reductions in North America and Europe. Other operating expenses for the nine months ended September 30, 2024, included a fee of $0.5 million in connection with the receipt of employee retention tax credits, restructuring costs of $0.6 million in connection with headcount reductions, and $0.3 million related to settlement of an unclaimed property audit.
Interest expense
Interest expense increased $0.2 million, or 8.6%, to $2.6 million for the nine months ended September 30, 2025, compared with $2.4 million for the nine months ended September 30, 2024. The increase was primarily due to a higher effective interest rate during the period compared to the prior year.
Loss on equity securities
During the nine months ended September 30, 2024, we sold all of our remaining Harvard Apparatus Regenerative Technology Inc. (“HRGN”) stock for $1.9 million and recorded a loss on equity securities of $1.6 million. We did not hold any shares of HRGN stock during the nine months ended September 30, 2025.
22
Table of Contents
Income tax benefit
The income tax expense (benefit) was $(0.3) million and $0.2 million for the nine months ended September 30, 2025 and 2024, respectively. The effective tax rates for the nine months ended September 30, 2025 and 2024 were 0.6% and (1.4)%, respectively. The higher effective tax rate during the nine months ended September 30, 2025, compared to the nine months ended September 30, 2024, was primarily due to the tax effect of goodwill impairment and the release of reserves related to uncertain tax positions.
Liquidity and Capital Resources
Our primary sources of liquidity are cash and cash equivalents, internally generated cash flow from operations and our shelf registration statement that provides for the issuance of common stock, preferred stock, warrants and units up to an amount equal to $100 million. Our expected cash outlays relate primarily to cash payments due under our Credit Agreement described below as well as salaries, inventory, and capital expenditures. We held cash and cash equivalents of $6.8 million and $4.1 million as of September 30, 2025 and December 31, 2024, respectively. Borrowings outstanding, net of unamortized deferred financing costs, were $34.0 million and $37.0 million as of September 30, 2025 and December 31, 2024, respectively.
The Coronavirus Aid, Relief, and Economic Security Act of 2020 (the “CARES Act”) provided an employee retention tax credit (“ERTC”) that was a refundable tax credit against certain employer taxes. The Company has received ERTC refunds of $5.4 million as of September 30, 2025. The Company’s compliance with the program’s qualifications may be subject to audit through May 2029, which is when the statute of limitation expires.
We maintain the Credit Agreement, which originally provided for a term loan of $40.0 million and a $25.0 million revolving credit facility with an original maturity of December 22, 2025. On March 10, 2025, we entered into an amendment to the Credit Agreement (the “March 2025 Amendment”). The March 2025 Amendment provided, among other things, that the Lenders’ commitment under our revolving credit facility would be capped at $12.65 million, which was the amount outstanding thereunder as of the date thereof, and thus we are unable to make additional borrowings under our revolving credit facility. The March 2025 Amendment also established certain Refinancing Milestones in connection with the refinancing of the Credit Agreement (the “Refinancing”), including receipt of a term sheet or commitment letter from one or more potential lenders, by the dates provided in the March 2025 Amendment, and the Company's consummation of the Refinancing by June 30, 2025. Pursuant to the March 2025 Amendment, the Lenders also agreed not to assert any breaches of the financial covenants included in the Credit Agreement for the first quarter of fiscal year 2025 provided that we continued to comply with our payment obligations, achieved the Refinancing Milestones, maintained minimum liquidity (defined as the sum of (a) unrestricted cash and cash equivalents and (b) the amount by which the aggregate amount committed under the Company’s revolving credit facility exceeds the total amount drawn under the credit facility) of $3.5 million and provided the administrative agent with certain financial reports. In addition, pursuant to the terms of the March 2025 Amendment the applicable interest rate margin was increased such that interest rate was equal to a rate per annum based on the Secured Overnight Financing Rate (“SOFR”) plus 400 bps and amortization payments were revised so that a proportionate payment must be made on a monthly rather than a quarterly basis.
As of June 30, 2025, we were not in compliance with the Refinancing Milestones and quarterly financial covenants contained in the March 2025 Amendment. On August 8, 2025, we entered into the August 2025 Amendment Agreement, pursuant to which the Lenders and administrative agent agreed, subject to the terms contained in the August 2025 Amendment, to waive the events of default due to the Company’s failure to achieve certain Refinancing Milestones and its failure to comply with the consolidated net leverage ratio covenant and the consolidated fixed charge coverage ratio covenant as of the June 30, 2025 test date. Pursuant to the terms of the August 2025 Amendment, the Lenders also agreed not to test the net leverage ratio financial covenant and the consolidated fixed charge coverage ratio financial covenant for the fiscal quarter ended September 30, 2025, and to reduce the Company’s covenant to maintain minimum liquidity (defined as the sum of (a) unrestricted cash and (b) the amount by which the aggregate amount committed under the Company’s revolving credit facility exceeds the total amount drawn under the credit facility) of $3.0 million. The August 2025 Amendment also added as a mandatory prepayment event the receipt of cash proceeds upon a Refinancing or upon the sale of the equity interests or all or substantially all of the assets of the Company. In addition, pursuant to the terms of the August 2025 Amendment, the applicable interest rate margin was increased such that the interest rate is equal to a rate per annum based on the SOFR plus 700 bps. In connection with the August 2025 Amendment, the Company has also agreed to accomplish steps towards the Refinancing or repayment of the Credit Agreement by no later than December 5, 2025. The Company continues to make progress on these steps, and is working actively to reach a definitive agreement that will accomplish one of these outcomes. The failure to accomplish such steps on the agreed timeline shall constitute an event of default under the Credit Agreement. In such event, in addition to other actions the Lenders may require, the amounts outstanding under the Credit Agreement may become immediately due and payable.
23
Table of Contents
The Company continues to explore alternative sources of capital that would allow it to refinance the outstanding indebtedness under the Credit Agreement, but its ability to access such other sources of capital is uncertain.
There is no assurance that such capital will be available, be obtainable on commercially acceptable terms, or provide the Company with sufficient funds to meet its objectives. Based on its anticipated cash flows from operations, unless the Company is able to access other sources of capital or extend the date for repayment under the Credit Agreement, the Company will be unable to pay its debt obligations and fund its operations for at least twelve months from the date of issuance of the unaudited consolidated financial statements contained in this Quarterly Report on Form 10-Q. As a result, there is substantial doubt about the Company's ability to continue as a going concern.
CONDENSED CONSOLIDATED CASH FLOW STATEMENTS
Nine Months Ended September 30,
(in thousands)
2025
2024
Net cash provided by (used in) operating activities
$
6,825
$
(285
)
Net cash used in investing activities
(1,264
)
(878
)
Net cash (used in) provided by financing activities
(3,740
)
1,226
Effect of exchange rate changes on cash
888
223
Increase in cash and cash equivalents
$
2,709
$
286
Net cash provided by (used in) operations was $6.8 million and $(0.3) million for the nine months ended September 30, 2025 and 2024, respectively. Cash flow from operations for the nine months ended September 30, 2025 was positively impacted by a reduction in accounts receivable of $2.8 million, a reduction in inventories of $1.6 million, and $2.2 million of cash inflows from ERTC refunds received.
Net cash used in investing activities was $1.3 million for the nine months ended September 30, 2025, compared to cash used in investing activities of $0.9 million for the nine months ended September 30, 2024. Cash used in investing activities for the nine months ended September 30, 2025 consisted of $1.3 million of capital expenditures for manufacturing and capitalized software development. Cash used in investing activities for the nine months ended September 30, 2024 consisted of $2.8 million of capital expenditures for manufacturing and information technology infrastructure and software development, offset by $1.9 million in proceeds from the sale of marketable equity securities.
Net cash (used in) provided by financing activities was $(3.7) million and $1.2 million for the nine months ended September 30, 2025 and 2024, respectively. During the nine months ended September 30, 2025, we made $3.0 million in debt repayments on our term loan and paid $0.7 million in debt issuance costs as part of the March 2025 Amendment and the August 2025 Amendment. During the nine months ended September 30, 2024, debt outstanding under our credit facility increased by $1.2 million, consisting of net borrowings under our revolver of $6.2 million, and payments of $5.0 million against the term loan.
Impact of Foreign Currencies
Our international operations in some instances operate in a natural hedge, as we sell our products in many countries and a substantial portion of our revenues, costs and expenses are denominated in foreign currencies, primarily the euro and British pound.
During the three months ended September 30, 2025, changes in foreign currency exchange rates resulted in a favorable effect on revenues of $0.3 million and an unfavorable effect on expenses of $0.6 million. During the nine months ended September 30, 2025, changes in foreign currency exchange rates resulted in a favorable effect on revenues of $0.6 million and an unfavorable effect on expenses of $0.9 million.
The gain (loss) associated with the translation of our foreign equity into U.S. dollars included as a component of other comprehensive loss was $(0.8) million and $1.6 million for the three months ended September 30, 2025 and 2024, respectively, and $3.1 million and $0.7 million for the nine months ended September 30, 2025 and 2024, respectively.
Currency exchange rate fluctuations included as a component of net loss resulted in currency gain (loss) of $0.0 million and $(0.4) million for three months ended September 30, 2025 and 2024, respectively, and $0.6 million and $(0.5) million for both the nine months ended September 30, 2025 and 2024, respectively.
24
Table of Contents
Critical Accounting Policies
There have been no material changes to the critical accounting policies underlying the accompanying unaudited consolidated financial statements and as set forth in Part II, Item 7 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Recent Accounting Pronouncements
For information on recent accounting pronouncements impacting our business, see “Recently Issued Accounting Pronouncements Yet to Be Adopted” included in Note 1 to our Condensed Consolidated Financial Statements included in Part I, Item 1. of this report.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Not Applicable.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.